Abstract 387P
Background
The prevalence of tobacco use has significant implications for the global economy, since it is the leading cause of death and disease worldwide. Currently, tobacco-related factors contribute to an estimated 8 million deaths annually, with a majority of these fatalities concentrated in low- and middle-income countries. The objective of this study was to perform a thorough evaluation of existing literature concerning tobacco use and cancer prevalence across Indian tribal tribes, with the aim of ascertaining the prevalence, distribution, and factors that contribute to tobacco use, which is necessary for the purpose of developing and modifying control strategies aimed at mitigating tobacco consumption among this marginalized community.
Methods
A systematic review was undertaken to examine the available evidence on the oral health status, tobacco use, and cancer prevalence among tribal groups in India. The review was registered in the PROSPERO database. Sources published from 1980 to 2023 from reputable databases like PubMed, Crossref, Google Scholar, and Web of Science were used in this evaluation.
Results
The findings of this study encompass a comprehensive analysis of 22 distinct tribal population involving 28,572 individuals. The prevalence of tobacco consumption varied between 12% and 42.5%. In the context of gender-specific studies, the prevalence of tobacco use among females varied between 1.2% and 12%, whereas among males it ranged from 15% to 52%. The prevalence of oral cancer in this marginalized community ranged from 5% to 12%, as assessed. In contrast, the consumption of smokeless tobacco was prevalent throughout the indigenous community. The primary risk factors for tobacco use were identified as a dearth of information regarding oral health, deeply entrenched dental attitudes, and limited accessibility to health services.
Conclusions
To effectively address the issue of tobacco use, it is imperative to prioritize additional research on improved methodologies, evidence-based policies, and viable options for tobacco cessation. This review recommends implementing campaigns and abstinence as an effective strategy for mitigating the adverse consequences.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
280P - Radium-223 for patients with metastatic castration-resistant prostate cancer with symptomatic bone metastases progressing after first-line abiraterone or enzalutamide: One institutional experience
Presenter: Keng Man Chiang
Session: Poster Display
Resources:
Abstract
281P - 10-year treatment outcome of prostate cancer patients with 3D conformal radiation: Experience of a single cancer institution in Iran
Presenter: Reyhane Bayani
Session: Poster Display
Resources:
Abstract
282P - Predictors of outcomes in patients with clinically lymph node-positive prostate cancer after definitive radiotherapy
Presenter: Jae-Sung Kim
Session: Poster Display
Resources:
Abstract
283P - Radiotherapy utilization rate and treatment patern of protate cancer at Cipto Mangunkusumo Central General Hospital (RSCM): What we learn from pre-pandemic era
Presenter: Riyan Apriantoni
Session: Poster Display
Resources:
Abstract
284TiP - CYCLONE 3: A phase III, randomized, double-blind, placebo-controlled study of abemaciclib in combination with abiraterone plus prednisone in men with high-risk metastatic hormone-sensitive prostate cancer
Presenter: Nobuaki Matsubara
Session: Poster Display
Resources:
Abstract
292P - Comparative characteristics of early cervical cancer diagnosis methods for Tashkent women
Presenter: Gulnoza Goyibova
Session: Poster Display
Resources:
Abstract
293P - Carboplatin in locally advanced cervical cancer treated with chemoradiation: An alternative to cisplatin
Presenter: Natalia Isabel Valdiviezo Lama
Session: Poster Display
Resources:
Abstract
294P - Concurrent chemoradiation with cisplatin every 3 weeks in locally advanced cervical cancer: A single arm phase II clinical trial
Presenter: Long Nguyen
Session: Poster Display
Resources:
Abstract
295P - A prospective study of dose escalated simultaneous integrated boost in node-positive cervical cancer
Presenter: Ritusha Mishra
Session: Poster Display
Resources:
Abstract
296P - Safety, efficacy, and immunogenicity of therapeutic vaccines for patients with high-grade cervical intraepithelial neoplasia (CIN 2/3) associated with human papillomavirus: A systematic review
Presenter: Caroline Amélia Gonçalves
Session: Poster Display
Resources:
Abstract